Audit Report Tv)
Report No: 0713308726
Version 1

Product Service

2.5.5 Design and Development

Subsystem Design and Development
Audit tal Martin Szepannek / George Pavlov / Gabriele Mousset / Honorata Donnermair / Melanie Gaen
Area(s) visited | Location # 10578
(location, e.g., | For more details related to audit location and time refer to chapter 2.2 of this report.
site visited)

Audit criteria
according to

"Design and Development: Identification of Devices Subject to Design and Development Procedures; Technical Documentation (MDSAP Chapter 5, Task 1, Site:
10578);
(DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 7.1, 7.3.10 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 7.5.3, 8.1, 8.4 + MDSAP - Australia - TG(MR)R Schedule 3, Part, (excluding

audit plan or including clause 1.6) + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.7, 4.2 + MDSAP - Canada - CMDR 9, 10 to 20 + MDSAP - Japan - M0169: 5-1, 6, 26, 36-
2; [Old: 5, 6, 26] + MDSAP - USA - 21 CFR 820.30(a) + MDR - Article 10.1, 10.2, 10.9 3 (e, g); Annex IX 2.2 [2 (c2) + MDD - Annex II (3.2), Annex V (3.2), Annex
VI (3.2)"
Design and Development: Selection of a Completed Design and Development Project (MDSAP Chapter 5, Task 2, Site: 10578
"Design and Development: Design and Development Planning (MDSAP Chapter 5, Task 3, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.3.2 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.3.2 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(4)8(5)(c) + MDSAP - Brazil -
RDC ANVISA 16/2013: 4.1.2, 4.1.11 + MDSAP - Canada - CMDR 32 + MDSAP - Japan - M0169: 6, 26, 30 + MDSAP - USA - 21 CFR 820.30(b), 820.30()) + MDR
- Article 10.9 [3 (g) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"
"Design and Development: Implementation of the Design and Development Process (MDSAP Chapter 5, Task 4, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.3.1, 7.3.10 + (DIN)(EN) ISO 9001 - 7.5.1, 7.5.3, 8.3.1 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(4)8(5)(c) + MDSAP - Brazil
- RDC ANVISA 16/2013: 4.1.1 + MDSAP - Japan - MO169: 6, 30, 36-2; [Old: 6, 30] + MDSAP - USA - 21 CFR 820.30(a), 820.30(c), 820.30()) + MDR - Article
10.9 3 (g) + MDD - Annex II (3.2)"
"Design and Development: Design and Development Input (MDSAP Chapter 5, Task 5, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 5.2, 7.2.1, 7.3.3, 8.2.1 + (DIN)(EN) ISO 9001 - 5.1.2, 7.5.1, 8.2.2, 8.3.3, 8.5.5, 9.1.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2,
Sch3 P1 Cl 1.4(2)&(5)(c), Sch 3 P1 1.4(3)(a)&(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.3, 4.1.11 + MDSAP - Canada - CMDR 10-20, 21-23, 66, 67,
68 + MDSAP - Japan - M0169: 6, 11, 27, 31, 55-1; [Old: 6, 11, 27, 31, 55] + MDSAP - USA - 21 CFR820.30(c), 820.30(g) + MDR - Article 10.9 [1 s2, 10.9 3 (b),
10.11; Annex IX 2.2 [2 (c2, c6, c8); Article 1 (3), Article 1 (4, 6, 7, 8, 9), Article 2 (1) + MDD - Annex II (3.2)"
"Design and Development: Completeness, Coherence, and Unambiguity of Design and Development Input (MDSAP Chapter 5, Task 6, Site: 10578);
(DIN)(EN) ISO 13485 - 7.3.3 + (DIN)(EN) ISO 9001 - 8.3.3 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013:
4.1.3 + MDSAP - Japan - M0169: 31 + MDSAP - USA - 21 CFR820.30(c)"
"Design and Development: Design and Development Output and Design Verification (MDSAP Chapter 5, Task 7, Site: 1078);
(DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.3.4 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.5 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(5)(c) + MDSAP - Brazil - RDC.
ANVISA 16/2013:4.1.5, 4.1.4, 4.1.11 + MDSAP - Japan - M0169: 6, 7-2, 32; [Old: 6, 32] + MDSAP - USA - 21 CFR 820.30(d), 820.30(f) +MDR- Article 10.9
{13 (b); Annex IX 2.2 2 (c5) + MDD - Annex II (3.2)"
"Design and Development: Risk Management Activities Applied Throughout the Design and Development Project (MDSAP Chapter 5, Task 8, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.3.3, 7.3.4 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.3.3, 8.3.5 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P14 Cl 1.4(5)(c)\iii)
+MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.11, RDC ANVISA 56/2001 + MDSAP - Canada - CMDR 10, 11, 15, 16 + MDSAP - Japan - M0169: 6, 26, 31,
32 + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.9 [3 (e) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"
"Design and Development: Design Verification or Design Validation to Confirm Effectiveness of Risk Control Measures (MDSAP Chapter 5, Task 9, Site: 10578);
(DIN)(EN) ISO 13485 - 7.1, 7.3.6, 7.3.7 + (DIN)(EN) ISO 9001 - 8.1, 8.3.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(5)(c) + MDSAP - Brazil -
RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.11. + MDSAP - Canada - CMDR 10,11, 15, 16 + MDSAP - Japan - M0169: 26, 34, 35-1, [Old: 26, 34, 35] + MDSAP.
- USA - 21 CFR 820.30(f), 820.30(g) + MDR - Annex IX 2.2 2 (c5) + MDD - Annex II (3.2)"
"Design and Development: Design Validation (MDSAP Chapter 5, Task 10, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.3.7 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2; Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC
ANVISA 16/2013: 2.4, 4.1.8, 4.1.11 + MDSAP - Canada - CMDR 12, 18, 19 + MDSAP - Japan - MO169: 6, 35-1; [6, 35] + MDSAP - USA - 21 CFR 820.30(g) +
MDR - Article 10.3, 10.9 3 (f);_ Annex IX 2.2 [2 (c5); Annex XIV, Article 61, and Annex XIV part A + MDD - Annex Il (3.2)"
"Design and Development: Clinical Evaluation and/or Evaluation of Medical Device Safety and Performance (MDSAP Chapter 5, Task 11, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.3.7 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Australia - TG(MD)R Reg 3.11, Sch1 EP14, Sch3 P1 Cl 1.4(5)(c)(vii), Sch3
P8 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.8, 4.1.11, RDC ANVISA 56/2001 + MDSAP - Canada - CMDR 12, 18, 19 + MDSAP - Japan - MO168: 6, 35-1;
[Old: 6, 35] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.3, 10.9 [3 (f); Annex IX 2.2 §[2 (c5); Annex XIV, Article 61, and Annex XIV part A + MDD -
Annex II (3.2)"
"Design and Development: Software Design and Development (MDSAP Chapter 5, Task 12, Site: 10578);
(DIN)(EN) ISO 13485 - 7.3.2, 7.3.10 + (DIN)(EN) ISO 9001 - 7.5.3, 8.3.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch1 EP12.1 + MDSAP - Brazil - RDC
ANVISA 16/2013: 2.4, 4.1.8, 4.1.11 + MDSAP - Canada - CMDR 20 + MDSAP - Japan - M0169: 30, 36-2; [Old: 30] + MDSAP - USA - 21 CFR 820.30(g) +
MDR - Article 10.9 3 (g) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"
"Design and Development: Design and Development Change (MDSAP Chapter 5, Task 13, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.3.9, 7.3.10, 8.2.1 + (DIN)(EN) ISO 9001 - 7.5.1, 7.5.3, 8.1, 8.3.6, 8.5.5, 8.5.6, 9.1.2 + MDSAP - Australia - As required
by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.10, 4.1.11, Brazilian Law 6360/76 - Art. 13 + MDSAP - Canada - CMDR 1,
34 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - 21 CFR 820.30(i), 807 + MDR- Article 10.9 [1 s2, 10.9913 (a); Annex IX 2.2 [2
(ct, 08); Article 8, Article 9 + MDD - Annex II (3.2)"
"Design and Development: Design Review (MDSAP Chapter 5, Task 14, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 7.3.2, 7.3.5 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.2, 8.3.4 + MDSAP - Australia - TG(MD)R Sch3 P1 C1.4(5)(c)(i) + MDSAP - Brazil -
RDC ANVISA 16/2013: 4.1.6, 4.1.11 + MDSAP - Japan - M0169: 6, 30, 33 + MDSAP - USA - 21 CFR 820.30(e) ++ MDR- Article 10.9 93 (b); Annex IX 2.2 2
(2); Annex XI 6.2 2 + MDD - Annex II (3.2)"
"Design and Development: Impact Review of Design and Development Changes on Previously Made and Distributed Devices (MDSAP Chapter 5, Task 15, Site:
10578);
(DIN)(EN) ISO 13485 - 7.3.9 + (DIN)(EN) ISO 9001 - 8.3.6, 8.5.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.10 + MDSAP - Japan - M0169: 36-1; [Old: 36]
+ MDSAP - USA - 21 CFR 820.30(i) + MDR- Article 10.9 1 s2, 10.99]3 (a); Annex IX 2.2 [2 (c1, c8); Article 8, Article 9+ MDD - Annex II (3.2)"
"Design and Development: Design Transfer (MDSAP Chapter 5, Task 16, Site: 10578);
(DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.3.8 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.7, 4.1.9, 4.1.11, 4.2 + MDSAP -
Japan - MO169: 6, 7-2, 35-2; [Old: 6, 30] _ + MDSAP - USA - 21 CFR 830.30(h) + MDR - Article 10.9 [3 (g) + MDD - Annex II (3.2)"
"Design and Development: Top Management Commitment to Design and Development Process (MDSAP Chapter 5, Task 17, Site: 10578);
(DIN)(EN) ISO 13485 - 4.1.3, 5.1, 5.5.1 + (DIN)(EN) ISO 9001 - 4.4, 5.1.1, 5.3, 8.4 + MDSAP - Australia - TG(MD)R Sch P14 Cl 1.4(5)(b)(ii) + MDSAP - Brazil -
RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MO169: 5, 10, 15 + MDR - Article 10.9 13 (c) + MDD - Annex II (2, 3.1)"
EN ISO 18562 (Biocompatibility evaluation of breathing gas pathways)

Brief “e*Trails (GP)

description of
processes or
activities
evaluated to
demonstrate
what was
audited related
to the listed
key QMS
documents
and records
reviewed
below
considering
inputs,
outputs, and
measures

ID: 31505

D&D #1 - &ldentification of devices subject to design and development procedures; technical documentation (GP)
The processes are defined and documented as set of procedures : DWAG IN 4200 is established ad applicable to
medical and non-medical devices.

The stage -gate is process is defined with 8 stages, whereas first 3 stage-gates form pre-design concepts phase.
All design changes are following SOP Design Change Process.

Start with Gate 3.0 Preparation ==> 4.0 Definition ==> 4.1 Design ==> 5.0 Realization ==> 6.0 Validation ==> 7.0 CE /
Ramp-up / Market Launch ==> 7.1 Serial Production ==> Gate 8.0 Life Cycle/Change

Changes are managed according to Design Change Process

The system used for documentation for Design requirements is IBM Engineering Requirements Management Tool
DOORS.

The procedure defines criteria, as applicable for

* new product development

* module development

+ Upgrades and product change

* Introduction of OEM or private label

+ Intro. Trading goods

+ Transfer of development, production or other disciplines

Doc No: MED_T_09.50 Revision: 12 — released Effective: 28 May 2021 Page 30 of 107
